West Lake University Anti -Cross Disease Oral Medicine was approved for clinical trial

News from West Lake University, after more than two years of hard work, Yu Hongtao, dean of the School of Life Sciences and director of the West Lake Laboratory, led the coronary virus oral drugs developed by the corporation team.The trial center was approved and recently entered the clinical trial stage.It is reported that China has completely independent intellectual property for the drug.

According to the surging news report, WPV01 developed by West Lake University, targeting the key protease 3CLPRO in the process of self -replication of coronal virus.The replication of coronal virus began with the combination of S protein, which is virus and the receptor ACE2 on the host cell. After that, the virus genome RNA enters the host cells and translates to the polypeptide chain by the host ribosome.The newly -generated polypeptide chain is catalyzed and cut by PLPRO and 3CLPRO, which is catalyzed by the two proteases of proteases, and generates non -compatible proteins required for virus replication.Therefore, inhibiting 3CLPRO can block the replication of coronal virus.

In March 2020, the research team of the West Lake University began to prepare the coronary virus 3clPro protein sample, and then used the DNA encoding compound screening technology to guide the compound molecular screening.Monthly determines the candidate drug molecules through activity testing and functional verification.

In the next two years, from computer auxiliary drug screening, structural analysis, compound binding mechanism analysis, activity test, to the research of compound salt, crystal, and dosage typeWPPV01, a drug molecule that entered clinical trials.

"Compared with Pfizer's Neymartov, although they are all targeted inhibitory 3CLPRO, Pfizer's drugs are a combination of covalent prices, and WPV01 is a combination of non -covalent prices. The combination mechanism is different.WPV01 is very competitive. "Hong Tao said," From cell to animals to test, WPV01 shows obvious advantages in terms of safety and effectiveness. "Virus (SARS-COV-2) variable strains, as well as other coronary viruses such as SARS-COV and Middle Eastern respiratory syndrome (MERS-COV), etc., have inhibitory effects.

Wang Tingliang, assistant to the president of West Lake University and the leader of results transformation, said that due to the rapid mutation of coronal virus, the treatment of crown disease in the future is likely to use "cocktail therapy"Play a combination of fist."The original small molecular drug developed by West Lake University is undoubtedly one of the timely and effective solutions given to the global anti -new crown virus epidemic."